Titre : Vietnam

Vietnam : Questions médicales fréquentes

Termes MeSH sélectionnés :

Hepatitis C
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vietnam : Questions médicales les plus fréquentes", "headline": "Vietnam : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vietnam : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-12", "dateModified": "2025-05-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vietnam" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Asie du Sud-Est", "url": "https://questionsmedicales.fr/mesh/D001210", "about": { "@type": "MedicalCondition", "name": "Asie du Sud-Est", "code": { "@type": "MedicalCode", "code": "D001210", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.252.145" } } }, "about": { "@type": "MedicalCondition", "name": "Vietnam", "alternateName": "Vietnam", "code": { "@type": "MedicalCode", "code": "D014744", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pham Quang Thai", "url": "https://questionsmedicales.fr/author/Pham%20Quang%20Thai", "affiliation": { "@type": "Organization", "name": "National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam; School of Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Viet Nam." } }, { "@type": "Person", "name": "Le Van Tan", "url": "https://questionsmedicales.fr/author/Le%20Van%20Tan", "affiliation": { "@type": "Organization", "name": "Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam." } }, { "@type": "Person", "name": "Marc Choisy", "url": "https://questionsmedicales.fr/author/Marc%20Choisy", "affiliation": { "@type": "Organization", "name": "Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; Centre for Global Health and Tropical Medicine, University of Oxford, UK." } }, { "@type": "Person", "name": "H Rogier van Doorn", "url": "https://questionsmedicales.fr/author/H%20Rogier%20van%20Doorn", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "H T Nguyen", "url": "https://questionsmedicales.fr/author/H%20T%20Nguyen", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Insights into Hepatitis C Virus E2", "datePublished": "2022-10-18", "url": "https://questionsmedicales.fr/article/36255318", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.jpcb.2c04697" } }, { "@type": "ScholarlyArticle", "name": "The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus.", "datePublished": "2023-10-21", "url": "https://questionsmedicales.fr/article/37894681", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/molecules28207201" } }, { "@type": "ScholarlyArticle", "name": "Global reporting of progress towards elimination of hepatitis B and hepatitis C.", "datePublished": "2023-02-08", "url": "https://questionsmedicales.fr/article/36764320", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S2468-1253(22)00386-7" } }, { "@type": "ScholarlyArticle", "name": "Is dual testing for hepatitis C necessary? Modelling the risk of removing hepatitis C antibody testing for Australian blood donations.", "datePublished": "2023-05-14", "url": "https://questionsmedicales.fr/article/37183505", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/vox.13430" } }, { "@type": "ScholarlyArticle", "name": "The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital.", "datePublished": "2023-04-11", "url": "https://questionsmedicales.fr/article/37041473", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12876-023-02750-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Asie", "item": "https://questionsmedicales.fr/mesh/D001208" }, { "@type": "ListItem", "position": 4, "name": "Asie du Sud-Est", "item": "https://questionsmedicales.fr/mesh/D001210" }, { "@type": "ListItem", "position": 5, "name": "Vietnam", "item": "https://questionsmedicales.fr/mesh/D014744" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vietnam - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vietnam", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vietnam", "description": "Comment diagnostiquer la dengue au Vietnam ?\nQuels tests pour le paludisme au Vietnam ?\nComment identifier la tuberculose ?\nQuels signes pour le choléra ?\nComment détecter une infection à VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vietnam", "description": "Quels symptômes de la dengue ?\nQuels signes du paludisme ?\nQuels symptômes de la tuberculose ?\nQuels signes du choléra ?\nQuels symptômes d'une infection à VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vietnam", "description": "Comment prévenir la dengue ?\nQuelles mesures pour prévenir le paludisme ?\nComment prévenir la tuberculose ?\nQuelles précautions contre le choléra ?\nComment prévenir le VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vietnam", "description": "Quel traitement pour la dengue ?\nComment traiter le paludisme ?\nQuel traitement pour la tuberculose ?\nComment traiter le choléra ?\nQuel traitement pour le VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vietnam", "description": "Quelles complications de la dengue ?\nQuelles complications du paludisme ?\nQuelles complications de la tuberculose ?\nQuelles complications du choléra ?\nQuelles complications du VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vietnam", "description": "Quels facteurs de risque pour la dengue ?\nQuels facteurs de risque pour le paludisme ?\nQuels facteurs de risque pour la tuberculose ?\nQuels facteurs de risque pour le choléra ?\nQuels facteurs de risque pour le VIH ?", "url": "https://questionsmedicales.fr/mesh/D014744?mesh_terms=Hepatitis+C&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la dengue au Vietnam ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests sanguins pour détecter les anticorps ou l'ARN viral." } }, { "@type": "Question", "name": "Quels tests pour le paludisme au Vietnam ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Un frottis sanguin ou un test de diagnostic rapide sont utilisés pour le paludisme." } }, { "@type": "Question", "name": "Comment identifier la tuberculose ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "La tuberculose est diagnostiquée par des tests cutanés, des radiographies et des cultures." } }, { "@type": "Question", "name": "Quels signes pour le choléra ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Le choléra se diagnostique par des selles liquides et des tests de laboratoire." } }, { "@type": "Question", "name": "Comment détecter une infection à VIH ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins spécifiques détectent les anticorps ou l'ARN du VIH." } }, { "@type": "Question", "name": "Quels symptômes de la dengue ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, douleurs articulaires, éruptions cutanées et fatigue sont fréquents." } }, { "@type": "Question", "name": "Quels signes du paludisme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Fièvre, frissons, sueurs, maux de tête et douleurs musculaires sont typiques." } }, { "@type": "Question", "name": "Quels symptômes de la tuberculose ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Toux persistante, perte de poids, sueurs nocturnes et fatigue sont courants." } }, { "@type": "Question", "name": "Quels signes du choléra ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Diarrhée aqueuse sévère, vomissements et déshydratation rapide sont caractéristiques." } }, { "@type": "Question", "name": "Quels symptômes d'une infection à VIH ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Symptômes initiaux incluent fièvre, fatigue, éruptions cutanées et ganglions enflés." } }, { "@type": "Question", "name": "Comment prévenir la dengue ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éliminer les eaux stagnantes et utiliser des répulsifs contre les moustiques." } }, { "@type": "Question", "name": "Quelles mesures pour prévenir le paludisme ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des moustiquaires, des insecticides et prendre des médicaments préventifs." } }, { "@type": "Question", "name": "Comment prévenir la tuberculose ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Vaccination BCG et dépistage des cas contacts sont essentiels pour la prévention." } }, { "@type": "Question", "name": "Quelles précautions contre le choléra ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Boire de l'eau potable, se laver les mains et consommer des aliments cuits." } }, { "@type": "Question", "name": "Comment prévenir le VIH ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des préservatifs et se faire dépister régulièrement pour prévenir le VIH." } }, { "@type": "Question", "name": "Quel traitement pour la dengue ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement est symptomatique, avec des analgésiques et une hydratation adéquate." } }, { "@type": "Question", "name": "Comment traiter le paludisme ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antipaludiques comme l'artémisinine sont utilisés pour traiter le paludisme." } }, { "@type": "Question", "name": "Quel traitement pour la tuberculose ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La tuberculose nécessite un traitement antibiotique prolongé, souvent sur six mois." } }, { "@type": "Question", "name": "Comment traiter le choléra ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le choléra est traité par réhydratation orale ou intraveineuse et antibiotiques si nécessaire." } }, { "@type": "Question", "name": "Quel traitement pour le VIH ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Le VIH est traité par des antirétroviraux pour contrôler la charge virale." } }, { "@type": "Question", "name": "Quelles complications de la dengue ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dengue sévère, le choc et des hémorragies." } }, { "@type": "Question", "name": "Quelles complications du paludisme ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Le paludisme peut entraîner des anémies, des convulsions et des défaillances organiques." } }, { "@type": "Question", "name": "Quelles complications de la tuberculose ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dissémination à d'autres organes et la résistance aux médicaments." } }, { "@type": "Question", "name": "Quelles complications du choléra ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La déshydratation sévère peut entraîner un choc hypovolémique et la mort." } }, { "@type": "Question", "name": "Quelles complications du VIH ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le VIH peut mener à des infections opportunistes et à des cancers associés." } }, { "@type": "Question", "name": "Quels facteurs de risque pour la dengue ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones tropicales, exposition aux moustiques et manque d'assainissement." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le paludisme ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Vivre dans des zones endémiques, absence de protection contre les moustiques." } }, { "@type": "Question", "name": "Quels facteurs de risque pour la tuberculose ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Conditions de vie précaires, immunodépression et contact avec des malades." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le choléra ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Accès limité à l'eau potable et à l'assainissement, ainsi que la consommation d'aliments contaminés." } }, { "@type": "Question", "name": "Quels facteurs de risque pour le VIH ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Relations sexuelles non protégées, partage de seringues et absence de dépistage." } } ] } ] }

Sources (10000 au total)

Global reporting of progress towards elimination of hepatitis B and hepatitis C.

The 69th World Health Assembly endorsed the global health sector strategy on viral hepatitis to eliminate viral hepatitis as a public health threat by 2030. Achieving and measuring the 2030 targets re... In 2020, using a questionnaire, we collected empirical, systematic, modelled, or surveyed data-reported by WHO country and WHO regional offices-on indicators of progress towards elimination of viral h... WHO received officially validated country-provided data from 130 countries or territories, and used partner-provided data for 70 countries or territories. We estimated that in 2019, globally, 295·9 mi... There has been notable global progress towards hepatitis elimination. In 2019, 30·4 million (10·3%) people living with hepatitis B knew their infection status, which was slightly higher than in 2015 (... World Health Organization....

Is dual testing for hepatitis C necessary? Modelling the risk of removing hepatitis C antibody testing for Australian blood donations.

Parallel testing of blood donations for hepatitis C virus (HCV) antibody and HCV RNA by nucleic acid testing (NAT) has been standard practice in Australia since 2000. Meanwhile, NAT technologies have ... A developed deterministic model calculated the RR of HCV transmission for four testing strategies. A low, mid and high estimate of the RR was calculated for each. The testing strategies modelled were ... The mid estimate of the RR was 1 in 151 million for universal dual testing, 1 in 111 million for targeted dual testing of first-time donors, 1 in 151 million for targeted dual testing for transfusible... Antibody testing in addition to NAT does not materially change the risk profile. Even conservative estimates for the cessation of anti-HCV predict an HCV transmission risk substantially below 1 in 1 m...

The care cascade for hepatitis C virus and prognosis of chronic hepatitis C patients treated with antiviral agents in a tertiary hospital.

Some studies have analyzed the frequency of HCV RNA testing and actual treatment among anti-HCV positive patients in Korea, which has a low prevalence of HCV infection. This study aimed to analyze the... Three thousand two hundred fifty-three anti-HCV positive patients presented to a tertiary hospital between January 2005 and December 2020. The number of patients who underwent HCV RNA testing, treatme... Of a total of 3,253 people, 1,177 (36.2%) underwent HCV RNA testing and 858 (72.9%) were positive for HCV RNA. 494 (57.6%) of HCV RNA positive patients received antiviral treatment, and 443 (89.7%) of... Owing to the introduction of direct-acting antivirals, high SVR...